Zealand Pharma

Share Issue/Capital Change • Sep 8, 2015

Copenhagen, 2015-09-08 11:23 CEST (GLOBE NEWSWIRE) -- 8 September 2015 –
Zealand announces that its share capital has been increased by nominal DKK
383,190 divided into 383,190 new shares with a nominal value of DKK 1 each. The
increase is a consequence of the exercise of employee warrants granted under
three of the company's warrant programs as described in the Articles of
Association.

The exercise price is DKK 94.60 per share for 308,582 of the new shares and DKK
77.00 per share for 74,608 of the new shares. The total proceeds to Zealand
from the capital increase amounts to DKK 34,936,673.20.

Each new share carries one vote at Zealand’s general meetings. The new shares
give rights to dividend and other rights from the time of the warrant holder's
exercise notice. Zealand only has one class of shares.

The new shares will be listed on Nasdaq Copenhagen following registration of
the capital increase with the Danish Business Authority. Following registration
of the new shares, the share capital of Zealand will be nominal DKK 23,901,298
divided into 23,901,298 shares with a nominal value of DKK 1 each.

The amendment of Zealand’s Articles of Association entailed by the share
capital increase has today been registered with the Danish Business Authority.
The new Articles of Association are attached to this announcement and are also
available on the company’s website: www.zealandpharma.com.

The content of this announcement has no impact on the company’s financial
guidance for 2015.

                                  ?????

For further information, please contact:

Hanne Leth Hillman, Senior Vice President, Investor Relations & Communications

Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotechnology
company with leading expertise in the identification, design and development of
novel peptide medicines. Zealand has a proprietary pipeline of novel medicines
and a portfolio of products and projects under license collaborations with
Sanofi, Helsinn Healthcare and Boehringer Ingelheim – primarily in the fields
of cardio-metabolic diseases and acute care indications.

The proprietary pipeline includes danegaptide for Ischemic Reperfusion Injury
in Phase II development and the stable glucagon analogue, ZP4207 in two
clinical development programs; as a ready-to-use rescue pen for severe
hypoglycemia in preparation for Phase II and as a multiple-dose version for
mild to moderate hypoglycemia in Phase I, as well as several preclinical
peptide therapeutics.

Zealand has invented lixisenatide, a once-daily prandial GLP-1 agonist, which
is marketed globally (ex-US) by Sanofi for the treatment of Type 2 diabetes.
Sanofi submitted lixisenatide for regulatory approval in the US in late July
2015, and has a combination of lixisenatide with insulin glargine (Lantus®) in
Phase III development with regulatory submissions expected in Q4 2015 in the US
and in Q1 2016 in Europe.

The company is based in Copenhagen (Glostrup), Denmark. For further information
about our business and activities, please visit: www.zealandpharma.com or
follow us on Twitter @ZealandPharma